The use of antipyschotic prescription for an university psychiatry clinic: A retrospective study;Bir üniversite kliniǧinde reçete edilen antipsikotik ilaçlar: Bir retrospektif çalişma

Klinik Psikofarmakoloji Bulteni

Volumn 16, Issue 3, 2006, Pages 160-166

  Sayin, Aslihan ^a,b   Karslioǧlu, Ersin ^a   Yavaş, Günseli ^a   Candansayar, Selçuk ^a  

^a GAZI UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Antipsychotic; Conventional; New generation; Switch

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

AFFECTIVE PSYCHOSIS; ARTICLE; DEMOGRAPHY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT; PRESCRIPTION; SCHIZOPHRENIA;

EID: 33749525503     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Chiu HFK, Shum PS. Psychotropic drug prescribing to chronic schizophrenics in a Hong Kong hospital. Int J Soc Psychiatry 1991; 37: 187-191
2. American Psychiatry Association. Practice guideline for the treatment of paitents with schizophrenia. Am J Psychiatry 1997; 154 (Suppl 15): S1-S6
3. Italian Collaborative Study Group on the Outcome of Severe Mental Disorders. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Eur J Clin Pharmacol 1999; 55: 685-690
4. Ungvari GS, Chung YG, Chee YK, Fung-Shing N, Kwong TW, Chiu HFK. The pharmacological treatment of schizophrenia in Chinese patients: a comparison of prescription patterns between 1996 and 1999. Br J Clin Pharmacol 2002; 54: 437-444
5. Hamann J, Ruppert A, Auby P, Pugner K, Kissling W. Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. Int J Psychopharmacol 2003; 18: 237-242
6. Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. ANZ J Psychiatry 2003; 37: 55-61
7. Sayin A, Karslioǧlu E, Yavaş G, Candansayar S, Coşar B. Antipsikotik ilaç başlanan hastalarin demografik yönden deǧerlendirilmesi. 39. Ulusal Psikiyatri Kongre Bildirileri Özet Kitabi, sayfa 28, Ekim 2003, Antalya
8. Karslioǧlu E, Yavaş G, Sayin A, Coşar B, Candansayar S. Klasik ve atipik antipsikotik kullanimi ve ilaç deǧiş iminin yillara ve tanilara göre deǧerlendirilmesi. 39. Ulusal Psikiyatri Kongre Bildirileri Özet Kitabi, sayfa 28, Ekim 2003, Antalya
9. Yavaş G, Sayin A, Karslioǧlu E, Candansayar S, Coşar B. Antipsikotik ilaç deǧişiminin nedenlerinin deǧerlendirilmesi. 39. Ulusal Psikiyatri Kongre Bildirileri Özet Kitabi, sayfa 28, Ekim 2003, Antalya
10. Blin O. A comparative review of new antipsychotics. Can J Psychiatry 1999; 44: 235-244
11. Remington G, Chong SA. Conventional versus novel antipsychotics: changing concepts and clinical implications. J Psychiatry Neurosci 1999; 24: 431-441
12. Chong MY, Tan CH, Fujii S, Yang SY, Ungvari GS, Si T, Chung EK, Sim K, Tsang HY, Shinfuku N. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 2004; 58: 61-67
13. Hermann RC, Yang D, Ettner SL, Marcus SC, Yoon C, Abraham M. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiat Serv 2002; 53: 425-430
14. Ghormann R, Engel RR, Geissler KH, Rüther E. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMPS study. Pharmacopsychiatry 2004; 37 (Suppl 1): S27-S38
15. Barak Y, Shamir E, Weizman R. Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A natiralistic, long-term, retrospective, comparative study. J Clin Psychopharmacol 2002; 22: 115-120
16. Labelle A, Bourget D, Boulay LJ, Ellis J, Tessier P. Switching outpatients wit schizophrenia and related disorders on long-acting injectable antispychotics to olanzapine: an open label naturalistic pilot study. J Clin Psychopharmacol 2002; 22: 545-553
17. Malla AK, Norman RMG, Kotleda V, Zirul S. Switching from therapy with typical antispychotic agents to risperidone: long-term impact on patient outcome. Clin Ther 2002; 24: 209-222
18. Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, Romano SJ. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine or risperidone in outpatients with schizophrenia. Schizophr Res 2004; 66: 101-113
19. Barak Y, Shamir E, Mirecki I, Weizman R, Aizenberg D. Switching elderly chronic psychotic patients to olanzapine. Int J Neuropsychopharmacol 2004; 7: 165-169
20. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 8: 457-472
21. Godleski LS, Goldsmith LJ, Vieweg WVR, Zettwoch N, Stikovac D, Lewis S. Switching depot antipsychotic drug responders to oral olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 141-144
22. Leucht S, Pitsche-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side effect of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and plasebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68